← Browse by Condition
Medical Condition
mantle cell lymphoma mcl
Total Trials
7
Recruiting Now
7
Trial Phases
Phase 1, Phase 2, Phase 1, Phase 2
Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas β€” each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.
Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.
Frequently Asked Questions — mantle cell lymphoma mcl Clinical Trials
How many clinical trials are currently recruiting for mantle cell lymphoma mcl?
ClinicalMetric currently tracks 7 actively recruiting clinical trials for mantle cell lymphoma mcl, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 7. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for mantle cell lymphoma mcl?
mantle cell lymphoma mcl research spans Phase 1 (3 trials), Phase 2 (4 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a mantle cell lymphoma mcl clinical trial?
Eligibility criteria for mantle cell lymphoma mcl trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 3
Phase 2 4
Top Sponsors
1 trial
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT06464861 Phase 1
Recruiting
Enrollment
52 pts
Location
China
Sponsor
Second Affiliated Hospital, Zh...
NCT06788652
Recruiting
Enrollment
300 pts
Location
United States
Sponsor
Juno Therapeutics, Inc., a Bri...
NCT04792489 Phase 2
Recruiting
Enrollment
315 pts
Location
United States, Canad...
Sponsor
Miltenyi Biomedicine GmbH
NCT07285590 Phase 2
Recruiting
Enrollment
50 pts
Location
Portugal, Spain
Sponsor
Grupo Español de Linfomas y Tr...
NCT04186520 Phase 1, Phase 2
Recruiting
Enrollment
100 pts
Location
United States
Sponsor
Medical College of Wisconsin
NCT05098613 Phase 1
Recruiting
Enrollment
68 pts
Location
United States
Sponsor
University of Colorado, Denver
NCT07272499 Phase 2
Recruiting
Enrollment
25 pts
Location
China
Sponsor
Ruijin Hospital
Related Conditions
primary mediastinal b cell lymphoma pmbcl (2) central nervous system lymphoma (2) diffuse large b cell lymphoma dlbcl (1) refractory diffuse large b cell lymphoma dlbcl (1) relapsed diffuse large b cell lymphoma (1) high grade b cell lymphoma hgbcl (1) transformed lymphoma (1) richter transformation (1) transplant ineligible 2nd line dlbcl (1) non hodgkin lymphoma nhl (1) chronic lymphocytic leukemia cll (1) follicular lymphoma (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology